TY - JOUR
T1 - Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure
AU - Singh, Sundeep
AU - Hynan, Linda S.
AU - Lee, William M.
N1 - Funding Information:
Conflict of interest Sundeep Singh and Linda Hynan have no conflicts of interest. William Lee has received research funding from Anadys, Boehringer-Ingelheim, Bristol-Myers-Squibb, Cumberland Pharmaceuticals, GlaxoSmithKline, Gilead, Merck, Novartis, Ocera Therapeutics, and Vertex. He has been a paid consultant for Novartis and a paid speaker for Merck.
PY - 2013/5
Y1 - 2013/5
N2 - Background: N-acetylcysteine (NAC) improves transplant-free survival in early coma grade (I-II) patients with non-acetaminophen induced acute liver failure (ALF). We determined whether the clinical benefit was associated with improvements in hepatic function. Methods: In a prospective, double blind trial, 173 ALF patients without evidence of acetaminophen overdose were stratified by coma grade (I-II vs. III-IV) and randomly assigned to receive either intravenous NAC or dextrose (placebo) for 72 h, resulting in four patient groups. INR, ALT, bilirubin, creatinine, and AST obtained on admission (day 1) and subsequent days (days 2-4) were used for secondary analysis performed by fitting longitudinal logistic regression models to predict death or transplantation or transplantation alone. Results: Treatment group and day of study in models including bilirubin or ALT were predictors of transplantation or death (maximum p < 0.03). Those patients with early coma grade who were treated with NAC showed significant improvement in bilirubin and ALT levels when compared to the other three groups (maximum p < 0.02 for NAC 1-2 vs. the 3 other treatments) when predicting death or transplantation. Treatment group, day of study, and bilirubin were predictors of transplantation (maximum p < 0.03) in ALF patients. Conclusion: The decreased risk of transplantation or death or of transplantation alone with intravenous NAC in early coma grade patients with non-acetaminophen induced ALF was reflected in improvement in parameters related to hepatocyte necrosis and bile excretion including ALT and bilirubin, but not in INR, creatinine, or AST. Hepatic recovery appears hastened by NAC as measured by several important lab values.
AB - Background: N-acetylcysteine (NAC) improves transplant-free survival in early coma grade (I-II) patients with non-acetaminophen induced acute liver failure (ALF). We determined whether the clinical benefit was associated with improvements in hepatic function. Methods: In a prospective, double blind trial, 173 ALF patients without evidence of acetaminophen overdose were stratified by coma grade (I-II vs. III-IV) and randomly assigned to receive either intravenous NAC or dextrose (placebo) for 72 h, resulting in four patient groups. INR, ALT, bilirubin, creatinine, and AST obtained on admission (day 1) and subsequent days (days 2-4) were used for secondary analysis performed by fitting longitudinal logistic regression models to predict death or transplantation or transplantation alone. Results: Treatment group and day of study in models including bilirubin or ALT were predictors of transplantation or death (maximum p < 0.03). Those patients with early coma grade who were treated with NAC showed significant improvement in bilirubin and ALT levels when compared to the other three groups (maximum p < 0.02 for NAC 1-2 vs. the 3 other treatments) when predicting death or transplantation. Treatment group, day of study, and bilirubin were predictors of transplantation (maximum p < 0.03) in ALF patients. Conclusion: The decreased risk of transplantation or death or of transplantation alone with intravenous NAC in early coma grade patients with non-acetaminophen induced ALF was reflected in improvement in parameters related to hepatocyte necrosis and bile excretion including ALT and bilirubin, but not in INR, creatinine, or AST. Hepatic recovery appears hastened by NAC as measured by several important lab values.
KW - ALF
KW - Acute liver failure
KW - N-acetylcysteine
UR - http://www.scopus.com/inward/record.url?scp=84878682848&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878682848&partnerID=8YFLogxK
U2 - 10.1007/s10620-012-2512-x
DO - 10.1007/s10620-012-2512-x
M3 - Article
C2 - 23325162
AN - SCOPUS:84878682848
SN - 0163-2116
VL - 58
SP - 1397
EP - 1402
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 5
ER -